Peripheral Membrane Interactions Boost the Engagement by an Anti-HIV-1 Broadly Neutralizing Antibody*

Received for publication, January 9, 2017, and in revised form, February 16, 2017 Published, JBC Papers in Press, February 17, 2017 DOI 10.1074/jbc.M117.775429

Edurne Rujas‡§1, Jose´ M. M. Caaveiro§2, Sara Insausti§, Miguel García-Porras‡, Kouhei Tsumoto‡3, and Jose´ L. Nieva‡4

From the ªBiofisika Institute (Consejo Superior de Investigaciones Científicas, UPV/EHU), and Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), 48080 Bilbao, Spain and the §Department of Bioengineering, Graduate School of Engineering, University of Tokyo, Tokyo, 113-8656, Japan

Edited by Charles E. Samuel

The 4E10 antibody displays an extreme breadth of HIV-1 neutralization and therefore constitutes a suitable model system for structure-guided vaccine design and immunotherapeutics against AIDS. In this regard, the relevance of autoreactivity with membrane lipids for the biological function of this antibody is still a subject of controversy. To address this dispute, herein we have compared the membrane partitioning ability of the 4E10 antibody and several of its variants, which were mutated at the region of the paratope surface in contact with the membrane interface. We first employed a physical separation approach (vesicle flotation) and subsequently carried out quantitative fluorescence measurements in an intact system (spectroscopic titration), using 4E10 Fab labeled with a polarity-sensitive fluorescent probe. Moreover, recognition of epitope peptide in membrane was demonstrated by photo-cross-linking assays using a Fab that incorporated the genetically encoded unnatural amino acid p-benzoylphenylalanine. The experimental data ruled out that the proposed stereospecific recognition of viral lipids was necessary for the function of the antibody. In contrast, our data suggest that nonspecific electrostatic interactions between basic residues of 4E10 and acidic phospholipids in the membranes contribute to the observed biological function. Moreover, the energetics of membrane partitioning indicated that 4E10 behaves as a peripheral membrane protein, tightening the binding to the ligand epitope inserted in the viral membrane. The implications of these findings for the natural production and biological function of this antibody are discussed.

*This work was supported by the National Institutes of Health and Basque Government Grants A0997051 and IT838-13 (to J. L. N.). Work in the Tsumoto laboratory was supported by Japanese Society for the Promotion of Science (JSPS) KAKENHI-A Grants 25249115 and 16H02420 (to K. T.), by the Platform for Drug Discovery, Informatics and Structural Life Science from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by JSPS KAKENHI-C Grant 15K06962 (to J. M. M. C.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

‡1 Recipient of a predoctoral fellowship from the Basque Government.

‡2 Present address: Laboratory of Global Healthcare, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan.

§3 To whom correspondence may be addresed: Dept. of Bioengineering, University of Tokyo, Bunkyo-ku, 113-8656 Tokyo, Japan. Tel.: 81-3-6409-2129; E-mail: tsamoto@k.u-tokyo.ac.jp.

§4 To whom correspondence may be addresed: Dept. of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), P.O. Box 644, 48080 Bilbao, Spain. Tel.: 34-94-601-3353; Fax: 34-94-601-3360; E-mail: gbpnies@lg.ehu.es.

The abbreviations used are: MPER, membrane-proximal external region; bNAb, broadly neutralizing antibody; CDR, complementarity determining region; NBD, 4-chloro-7-nitrobenz-2-oxa-1,3-diazole; pBPA, p-benzoylphenylalanine; PS, phosphatidylycerine; VL, virus-like; CL, cardiolipin; PI, phosphatidylinositol; PA, phosphatidic acid; PG, phosphatidylglycerol; PE, phosphatidylethanolamine; PC, phosphatidylcholine; ITC, isothermal titration calorimetry; PDB, Protein Data Bank; LUV, large unilamellar vesicle; Rho-PE, 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl); doxyl-PC, 1-palmitoyl-2-stearoyl-(5-doxyl)-sn-glycero-3-phosphocholine (16:0-5); PsV, pseudovirus.

Engagement by the 4E10 antibody of a conserved helical epitope on the membrane-proximal external region (MPER) of the Env gp41 subunit results in one of the broadest neutralization levels of HIV-1 reported to date (98% of viruses blocked in standard infectivity tests (1–3)). Prevalence of anti-MPER antibodies has been linked to neutralization breadth and potency of certain sera from chronically infected individuals (3, 4). Thus, solving the molecular mechanism that leads to viral blocking after MPER engagement by broadly neutralizing antibody (bNAb) 4E10 is critical in the fields of vaccine design and immunotherapy (3, 5–7). Because the viral membrane takes part in the stabilization of the MPER helix, it is generally accepted that antibodies targeting the MPER membrane site are polyspecific, showing a capacity to bind lipid moieties (8–12). In that respect, anti-MPER antibodies have been proposed to resemble natural antibodies that bind to phospholipids (13). Furthermore, it has been argued that HIV-1 may have evolved to escape anti-MPER responses by structural mimicry of the phospholipid ligands bound to autoantibodies (14). Following this line of evidence, some researchers consider anti-MPER antibodies as generally autoreactive and postulate that their natural production is limited by B-cell tolerance mechanisms (14–16).

Some experimental evidence suggesting that bNAb 4E10 binds to phospholipids, particularly anionic species such as phosphatidylserine (PS), cardiolipin (CL), or phosphatidylinositol (PI), has been obtained in several laboratories during the last decade (9, 10, 14, 17), which supported the notion of structural mimicry of phospholipid-binding sites by the antibody (13, 14). In agreement with that idea, the existence of a binding pocket accommodating the polar headgroup of PS or CL within the paratope of 4E10 was proposed (10). Strikingly, the structure of the paratope with lipid bound would differ from that of the paratope with peptide epitope bound (10). Nonethe-
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

FIGURE 1. Partitioning of the anti-MPER 4E10 Fab into membranes. A, 4E10 membrane partitioning detected in a sucrose gradient. Lipid vesicles incubated with the Fab were subjected to centrifugation. The sample was divided into four different fractions based on their different densities. An additional fraction employing SDS was collected, representing the material attached to the surface of the tube. The locations of the liposomes in the third and fourth fractions (i.e. floating fractions) were verified from the Rho-PE emission (bottom panels). The presence of Fab was probed by Western blotting. B, effect of the constituent lipids of the VL mixture on the process (lipid compositions are given in Table 1). 10E8 antibody was used as negative control (first row) and recovery of membrane binding by its replacement with other anionic phospholipids: PG, PI, PA, or CL. The band corresponding to the Fab was subjected to centrifugation. The sample was divided into four different fractions based on their different densities. An additional fraction floating fractions) were verified from the Rho-PE emission (indicated by the arrowheads; only in the first rows in B and C). SM, sphingomyelin; Chol, cholesterol.

less, some of these concepts have been challenged by the recent resolution of crystal structures of the unbound Fab form (18, 19) and Fab-lipid complexes (12, 20).

In particular, Irimia et al. (12) determined the crystal structure of the complex between 4E10 Fab and lipids such as phosphatidic acid (PA), phosphatidylglycerol (PG), and the lipid moiety glycerol phosphate, which revealed two binding sites on the paratope surface in contact with the membrane interface. Lipid recognition occurred primarily at the heavy chain complementarity determining region 1 (CDRH1) between the backbone atoms of the protein and the glycerol and phosphate moieties, which are the common components of phosphoglycerides. Thus, from these results it appears that the 4E10 Fab does not behave as a target-specific phospholipid-binding domain that performs selective-stereospecific recognition of ligand molecules (21). The crystallographic data were also consistent with the simultaneous accommodation of the phospholipid headgroup moieties and the bound peptide epitope within the 4E10 paratope and further underscored the role of the hydrophobic CDRH3 apex in establishing interactions with the lipid tails (12).

In an attempt to discern the role played by lipid interactions in the 4E10 neutralization mechanism, we have herein determined the specificity and intensity of its interactions with phospholipids in the context of biologically relevant bilayer systems. To that end, we have employed liposome flotation assays (a physical separation method) that were subsequently complemented with spectroscopic titration assays using Fabs labeled with the polarity-sensitive probe NBD. Moreover, a Fab 4E10 variant incorporating the UV-sensitive unnatural amino acid pBPA was used to monitor the specific recognition of the epitope peptide in a bilayer milieu. Our data indicated that direct partitioning of the 4E10 antibody from the aqueous phase into membranes is driven by favorable electrostatic interactions between the surfaces of the membrane and the paratope. Although not strictly required for its biological function, electrostatic forces were also beneficial for binding to the membrane-anchored epitope peptide, and these favorable interactions correlated with the neutralizing potency of the 4E10 antibody. Collectively, our observations support the view that favorable, albeit unspecific, interactions between 4E10 and lipids play a central role in the neutralization mechanism by increasing potency of the antibody, while keeping its broad coverage.

Results

Partitioning of 4E10 into Membranes Depends on Anionic Phospholipids—We first determined the partitioning of the 4E10 antibody into membranes using a vesicle flotation assay (Fig. 1A). We note that in these experiments the amount of antibody incubated with vesicles was kept the same under all conditions tested, even though the intensity of the bands among the different samples slightly fluctuated. The results displayed in Fig. 1B first reflected the different capacities of 10E8 and 4E10 antibodies for partitioning into virus-like (VL) membranes mimicking the viral envelope composition (22). The 10E8 antibody does not show lipid polyreactivity (3, 23) or insertion into membranes devoid of peptide epitope (24) and, consequently, was used as a negative control for membrane binding in our assays. Thus, whereas most of the 10E8 antibody was recovered from the high density fractions (Fig. 1B, first row), a major fraction of the input 4E10 antibody was recovered from the upper low density fractions, i.e. cofloating with the VL vesicles (Fig. 1B, second row). In search for a possible dependence of 4E10 binding to membranes on specific lipids, we subsequently established the contribution of each lipid present in the VL mixture to the process. Subtraction from the VL mixture of individual zwitterionic phospholipids (phosphatidylcholine (PC), or cholesterol one at a time, did not abolish membrane binding by 4E10 (Fig. 1B, third, fourth, and fifth rows; lipid compositions displayed in Table 1). Control experiments indicated that removal of zwitterionic and ubiquitous lipid phosphatidylcholine (PC) did not alter this antibody-vesicle binding pattern (data not shown). In contrast,
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

removal of the anionic PS from the composition of the vesicles prevented 4E10 to bind to the liposomes (Fig. 1C, first row). To determine whether binding was specific for PS or resulted from unspecific electrostatic effects, we replaced PS with other anionic phospholipid species (i.e. PG, PI, PA, or CL in Fig. 1C). The results convincingly showed that binding of 4E10 to liposomes was restored for all anionic phospholipids tested, indicating that membrane association did not require stereospecific recognition of a particular headgroup (21).

Basic Residues of the Paratope Promote Partitioning of 4E10 into the Membrane—The previous flotation experiments suggested that electrostatic interactions of 4E10 with anionic phospholipids promote its partitioning into membranes. Inspection of the surface of the paratope in contact with the membrane interface as inferred from the structure of Fab in complex with lipids (12) revealed a positively charged region (Fig. 2A). We sought to elucidate the relevance of this charged patch for the electrostatic interaction of 4E10 with the membrane by separately mutating the basic residues Arg-73 and Lys-100 by a Glu residue (R73E and K100E mutants, respectively; Fig. 2A). We assumed that such substitutions, reversing the charge of the affected residues, would reduce the net positive charge at the base of the paratope, making the antibody less prone to interact electrostatically with the negatively charged membranes. The analysis included a negative control designated as BS, in which residues Ser-28 and Ser-30 of the CDRH1 were mutated to Ala. These substitutions involved uncharged residues and therefore did not presumably alter the surface charge of the paratope even if involving residues located in the lipid-binding sites (12).

Fig. 2B illustrates the phenotypic traits resulting from the mutations with regard to membrane binding. To obtain a more robust comparison, these assays employed membranes containing high levels of PS (PC:PS 1:1, mole ratio). As expected from a model dominated by electrostatic interactions, most of the input WT antibody associated with the vesicles. In contrast, the binding of R73E to the vesicles was reduced by ~50%. The K100E mutant was not present in the floating fractions containing the vesicles, indicating even weaker tendency to partition into membranes. The negative BS control reproduced rather well the behavior of the WT antibody. We arrived at similar conclusions using VL vesicles (see below).

Charge-reversing Mutations Interfere with the Biological Function of 4E10—We next examined the role of electrostatic forces in the biological function of the 4E10 antibody using the same collection of antibodies described immediately above (Figs. 3 and 4 and Table 2). First, ITC experiments were conducted to evaluate the effect of the mutations on the affinity for the epitope peptide MPER(664–690) (Fig. 3A and Table 2). We have shown in previous ITC experiments that this peptide mimics better the C-terminal MPER epitopes than peptides truncated at position 683 (24). The values of $K_D$ determined from the binding isotherms were 4.6, 12.2, and 12.8 nm for the WT, BS, and R73E antibodies, respectively (Table 1), i.e. within the same range of affinity previously determined for the 10E8 antibody ($K_D$ 9.6 nm (24)). A more significant reduction of affinity (~20-fold) was observed in the case of the K100E mutant ($K_D$ = 91 nm).

To assess the effect of the mutations on epitope binding in a membrane context, flotation experiments were next carried out comparing the location of the Fab in the presence of bare VL vesicles or VL vesicles decorated with the peptide MPER(671–693) (Fig. 3B). This peptide has been shown to expose optimally the epitope region on the surface of lipid vesicles (24, 25). In the absence of peptide (Fig. 3B, left panel), the most

![FIGURE 2. Design of 4E10 mutants with exposed basic residues of the paratope. A, effect of R73E and K100E substitutions on the surface charge of the paratope. B, membrane partitioning as measured by flotation assays using vesicles containing 50 mol % of anionic lipid (PS) and PC. BS stands for a negative control with a double Ser to Ala substitution at positions 28 and 30 of the heavy chain.](image)
A conspicuous effect was observed for the K100eE mutant, which again did not appreciably associate with membranes in the VL system. As compared with WT or BS, a lower level of binding to LUVs was also evident for the R73E mutant. Incubation with VL-peptide complexes (Fig. 3B, right panel) resulted in the complete association of the WT and BS antibodies with vesicles. However, although a significant increase in binding to vesicles with respect to the bare vesicles was evident, association of R73E and K100eE variants with vesicles containing peptide was not complete.

The previous flotation results were obtained under conditions that promoted membrane partitioning (i.e. high lipid concentration (26)). To establish further differences in membrane affinities, binding to the vesicles as a function of the lipid concentration was monitored in dot blot assays (Fig. 3C). In this approach, measuring conditions were initially set up to reproduce the relative binding signals observed in flotation assays (i.e. to match signals of the Fabs recovered in the floating fractions). Titration of Fab-s with VL or VL-peptide complexes (Fig. 3C, left and right panels, respectively) confirmed the poor

---

**TABLE 1.** Thermodynamic parameters of binding.

| Mutant | ΔH (kJ/mol) | ΔS (J/K mol) | ΔG (kJ/mol) |
|--------|-------------|--------------|-------------|
| WT     | 25.3        | -43.1        | -37.9       |
| R73E   | 22.1        | -45.2        | -36.6       |
| K100eE | 21.5        | -45.7        | -36.2       |
| BS     | 23.2        | -44.5        | -37.8       |

**FIGURE 3.** Functional characterization of 4E10 mutants: binding to epitope peptide. A, binding isotherms of the MPER(664 – 690) epitope peptide to Fab 4E10 examined by ITC. The upper panel indicates the heat released upon consecutive injections of 10 μl of peptide solution (40 μM) into Fab (3 μM) in the calorimeter cell, and the lower panel indicates the integrated heats (symbols) and non-linear least squares fit (solid line) to the data using a one site binding model with the program ORIGIN 7.0. The thermodynamic parameters of binding are displayed in Table 1. Each titration was carried out once. B, flotation experiments in the presence of VL LUVs (left panel) or VL LUVs containing MPER(671–693) peptide (right panel). C, recognition of VL LUVs (left panel) or VL LUVs containing MPER(671–693) peptide (right panel) as determined by dot blot analysis. 2-fold serial dilutions of 500 μM LUVs and 10 μM peptide was spotted on the filters. BS, negative control with a double Ser to Ala substitution at positions 28 and 30 of the heavy chain.
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

performance of the charge-reversing R73E and K100eE mutants for partitioning into membranes, as well as their lower affinity for vesicles containing the epitope peptide.

To establish a correlation between biological function, binding to membrane-embedded epitope, and membrane partitioning, the potency of the antibody and mutants was evaluated in neutralization assays (Fig. 4A). The IC50 values determined for the mutants R73E and K100eE increased by approximately 1 order of magnitude with respect to WT and BS (Fig. 4A and Table 1). Interestingly, the R73E and BS mutants bound to peptide by ITC with almost equal affinity, but their neutralization potencies were significantly different (Table 1). These data demonstrated that mutations reducing the electrostatic charge in the vicinity of the paratope have a negative impact not only in the binding to the epitope inserted in vesicles, but also in the biological function of the antibody. In contrast, the BS mutant reproduced for the most part the behavior of the WT Fab. Dot blot assays indicated that the reduced levels of activity of the mutants correlated well with lower binding of the mutant antibodies to pseudovirus immobilized on a solid substrate (Fig. 4B). Overall, these results revealed a correlation between direct binding to immobilized pseudovirus (Fig. 4B) and direct binding to immobilized vesicles containing the epitope peptide (Fig. 3C, right panel).

Electrostatic Interactions Contribute to the Efficient Partitioning of 4E10 into Membranes—The left panel of Fig. 5A illustrates the difference in the conformation of the 4E10 CDRH3 loop in solution (PDB entry code 2FX7, gray) or embedded in a vesicle-like micellar structure made of dihexanoylphosphatidic acid (PDB entry code 4XBG, white). Based on this observation, a movement of the CDRH3 loop was proposed to occur upon interaction of the antibody with the membrane (12). According to this model, the Trp-100bHC at the tip of the CDRH3 would relocate within the membrane interface to a position roughly in the vicinity of the paratope (Fig. 5A, left bottom panel). The right panels of Fig. 5A display the changes in fluorescence that occur upon incubation of the NBD-Fab 4E10 with lipid vesicles. In the presence of VL vesicles, the fluorescence emission of the NBD probe replacing Trp at 100bHC increased toward shorter wavelengths, and its intensity increased. These two properties indicated that the dye (and therefore the apex of the CDRH3) its wavelength, and its intensity increased. These two properties indicated that the dye (and therefore the apex of the CDRH3) its being transferred from a solvent-exposed environment to a more hydrophobic environment (27). The additional illustration of the emission to longer wavelengths when vesicles contained Rho-PE (Fig. 5A, right bottom panel) or embedded in a vesicle-like micellar structure made of dihexanoylphosphatidic acid (PDB entry code 4XBG, white). Based on this observation, a movement of the CDRH3 loop was proposed to occur upon interaction of the antibody with the membrane (12). According to this model, the Trp-100bHC at the tip of the CDRH3 would relocate within the membrane interface to a position roughly equidistant from the headgroups and first methylene groups of the acyl chains of the lipids. Moreover, in a recent work we have shown that the polarity-sensitive NBD probe replacing Trp at the position 100b of the CDRH3 can be employed to monitor the insertion of the Fab 10E8 into the membrane (24). Here we have followed a similar strategy to characterize the association of 4E10 with membranes.

The right panels of Fig. 5A display the changes in fluorescence that occur upon incubation of the NBD-Fab 4E10 with lipid vesicles. In the presence of VL vesicles, the fluorescence emission of the NBD attached to 4E10 shifted toward shorter wavelengths, and its intensity increased. These two properties indicated that the dye (and therefore the apex of the CDRH3) being transferred from a solvent-exposed environment to a more hydrophobic environment (27). The right top panel of Fig. 5A additionally illustrates the shift of emission to longer wavelengths when vesicles contained Rho-PE. This phenomenon occurred as a consequence of the resonance energy transfer between the NBD(donor)-Rhodamine(acceptor) pair (27). As displayed in the right bottom panel of Fig. 5A, NBD fluores-

### TABLE 2
Thermodynamic parameters of binding of Fab 4E10 mutants to the MPER(664–690) peptide and their neutralization potencies

| Antibody (4E10) | K_m | ΔG° | ΔH° | TΔS | n | HXB2- IC_{50} | JRCSF- IC_{50} |
|-----------------|-----|-----|-----|-----|---|-------------|---------------|
| 4E10 WT         | 4.6 ± 1.5 | -11.4 ± 0.2 | -15.1 ± 0.2 | 3.7 | 1.0 ± 0.1 | 0.1 ± 0.02 | 0.21 ± 0.02 |
| BS              | 12.2 ± 2.5 | -10.8 ± 0.1 | -11.7 ± 0.1 | 0.9 | 1.3 ± 0.1 | 0.38 ± 0.03 | 1.59 ± 0.27 |
| R73E            | 12.8 ± 3.5 | -10.8 ± 0.1 | -14.7 ± 0.2 | 3.9 | 1.1 ± 0.1 | 5.3 ± 0.4 | 13.2 ± 3.5 |
| K100eE          | 91 ± 14 | -9.6 ± 0.2 | -10.4 ± 0.2 | 0.7 | 1.4 ± 0.1 | 3.3 ± 0.2 | 12.7 ± 4.0 |

* The errors were calculated from the fitting procedure with ORIGIN 7.0.

* * *
cence emission was also quenched by inclusion of 16:0–5 doxyl-PC in the lipid composition. The effects induced by these probes residing within the lipid bilayer demonstrated that NBD-Fab fluorescence changes were caused by the antibody-membrane interaction. Such effects were further consistent with the interfacial location of the Trp-100bHC predicted by the model displayed in the left panel of Fig. 5A.

We next analyzed the partitioning process quantitatively by monitoring the changes in NBD-Fab fluorescence that occur upon incubation of the Fab with increasing concentrations of VL large unilamellar vesicles (LUVs) (Fig. 5B, left panel). Consistent with the restrained interaction deduced from the flotation assays (Fig. 1C), the fluorescence of the NBD-Fab did not significantly change upon incubation with vesicles devoid of PS (Fig. 5B, right). The titration values adjusted to Equation 1 (Fig. 5C) from which a mole fraction partition coefficient \( K_x \) of 0.6 \( \times 10^6 \) was determined, a value that falls in the range of that observed for peripheral membrane proteins (28–30).

To evaluate the relative contribution of electrostatic interactions to the 4E10 partitioning process, titration experiments were conducted in a PC:PS model system (30, 31). Thus, \( K_x \) values were calculated for vesicles containing different mol percentages of monovalent acidic PS (Fig. 6). Association with vesicles increased with the PS content (Fig. 6, A and B), following the pattern predicted from a favorable contribution of electrostatic interactions (30). The plot of the observed partitioning free energy \( \Delta G_{\text{obs}} \) versus the surface potential \( \Psi_0 \) calculated using Equations 2 and 3, respectively (32, 33), yielded through extrapolation a \( \Delta G_{\text{obs}} \) value of approximately \(-5\) kcal mol\(^{-1}\) for membranes lacking net charge (Fig. 6C). This value indicates that, in the absence of anionic PS, a lipid concentration of \(-15\) mM would be required for 50% of the Fab initially in solution be bound to membrane. In contrast, the value measured for pure PS vesicles was much more favorable \( \Delta G_{\text{obs}} = -8.8 \) kcal mol\(^{-1}\). A simple calculation using Equation 2 reveals that lipid diluted 3 orders of magnitude (i.e. 17.5 \( \mu \)M) would be sufficient.
to attain a similar extent of Fab-membrane binding at room temperature.

Electrostatic Interactions Enhance Epitope Peptide Binding by the 4E10 Antibody—To infer the contribution of membrane partitioning to epitope recognition, we conducted experiments with PC:PS vesicles decorated with peptide epitope (Fig. 7). Consistent with previous flotation results (Fig. 4), the NBD emission spectra obtained upon incubation with vesicles containing 25 or 50% of PS revealed a favorable contribution of both anionic phospholipids and peptide epitope to Fab partitioning (Fig. 7A). Overall, the presence of peptide resulted in an increment of the partition constant, the effect being more pronounced with the highest proportion of PS (Fig. 7B).

To study in more detail the combined effect of electrostatic interactions with the membrane surface and peptide recognition, we next performed time course binding assays. Fig. 7C displays the kinetic traces of the changes of fluorescence intensity that occurred upon injection of NBD-Fab (arrow) in a solution containing LUVs (left panel), or a solution containing LUV-peptide complexes (right panel). The addition of antibody to vesicles containing PS (25 or 50%) resulted in both cases in a sudden increase of fluorescence intensity followed by a signal plateau, consistent with a fast association to the membrane. In contrast, upon addition of vesicles of the same composition containing the peptide, the sudden increase was followed by a second phase, in which the fluorescence signal increased gradually, leveling off at later times (Fig. 7C, right panel). Thus, whereas the fast phase of the NBD change can be explained by the spontaneous insertion into the membrane, the slower phase appears to be driven by specific peptide recognition. Interestingly, the peptide-dependent slower phase observed for the 50%
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

mol PS LUVs (Fig. 7C, right panel, red line) was faster than that observed with 25% mol PS. Thus, the PS appeared to have two effects. On the one hand, and as previously described, PS promoted higher levels of spontaneous incorporation. On the other hand, PS promoted faster recognition of the epitope peptide by the fraction of the Fab that had remained in solution.

Finally, to demonstrate peptide engagement under these conditions, we employed photo-cross-linking assays. To that end, the 4E10 Fab was modified with the UV-sensitive unnatural amino acid pBPA (34, 35), which was genetically encoded at position Trp-100bHC of the antibody as previously described for the Fab 10E8 (24). Formation of covalent adducts were detected only when the lipid vesicles harbored the MPER(671–693) peptide but not with vesicles devoid of peptide (Fig. 7C, insets).

4E10 Antibody Pre-equilibrated on the Membrane Is Competent for Epitope Engagement—Attachment of 4E10 molecules to virions without engagement to the epitope has been postulated as a mechanism favoring viral neutralization (36, 37). This two-step model assumes that the fraction of 4E10 antibody pre-bound to the membrane engages with gp41 when viral fusion is activated. Fig. 8 illustrates experiments to evaluate the capacity of the Fab for encountering and effectively engage the membrane-inserted epitope. To ensure that all Fab actually bound to membranes, we increased the lipid concentration in the assay, as well as the PS content in the vesicles. As explained in the diagram displayed in Fig. 8A, under these conditions the subsequent process of peptide engagement can be scored by photo-cross-linking assays.

As expected, NBD-Fab addition to vesicles composed of 100% PS resulted in an abrupt and comparable increase of fluorescence in the presence and in the absence of epitope peptides (Fig. 8B). The Fab-peptide complexes that could form under these conditions were subjected to UV light, and the formation of adducts was analyzed by SDS-PAGE and Western blotting (Fig. 8C). An additional band corresponding to cross-linked peptide (MPER(671–693)) and Fab HC was observed in samples of pBPA-Fab incubated with liposome-peptide complexes (lane 1). A similar outcome was observed when pBPA-Fab and peptide were incubated in the absence of vesicles (lane 2). In contrast, the adduct band was not detected upon pBPA-Fab incubation with liposomes that contained a peptide with crucial residues for antibody binding Trp-672 and Phe-673 mutated to Ala (lane 3). This negative control was included to assure that adducts formed within vesicles came from specific peptide binding and not from spontaneous cross-linking potentially promoted by the high densities of Fab and peptide attained at the membrane surface. Finally, a band corresponding to the Fab HC-peptide adduct was also observed when Fab was first pre-equilibrated on the membrane and peptide subsequently added to resulting liposome-Fab complexes (lane 4). These data clearly indicate that Fab pre-bound to membrane is competent in engagement with epitope.

Discussion
The Env complex embodies the entry machinery of the HIV-1 and constitutes its main antigen (38, 39). The gp41 MPER is highly conserved across the different HIV-1 strains.
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

and isolates and is functionally involved in assisting the membrane fusion process that culminates with cell infection (40–42). Because of its high degree of sequence conservation and the key role played by this element in the viral cycle, the bNAb 4E10 raised against the MPER exhibits an unusual neutralization breadth (5, 43, 44). It has been hypothesized that interactions with viral membrane lipids are required for the fulfillment of 4E10 biological function (9–12, 17, 36, 45–49). However, a systematic and quantitative assessment of 4E10 partitioning into membranes was lacking. A detailed examination of this process is important for two reasons: (i) to establish the lipid specificity range, which helps to evaluate the assumption that lipid auto-reactivity can prevent the production of 4E10-like antibodies through vaccination, and (ii) to establish the contribution of membrane-assisted MPER engagement to the biological function of 4E10.

Relevance of Spontaneous Partitioning for the Biological Function of 4E10

Our data in Figs. 1–6 demonstrate that 4E10 partitioning into membranes is promoted by unspecific electrostatic interactions between the negatively charged membrane surface and the basic residues exposed on the paratope and not by the stereospecific recognition of a particular phospholipid headgroup (21). In this regard, 4E10 can be considered a peripheral membrane protein employing concerted electrostatic and hydrophobic forces to insert into membranes and engage its epitope (for reviews, see Refs. 29, 50, and 51). Herein we have examined the factors intervening in the electrostatically driven partitioning of 4E10 in the membrane by employing two complementary approaches: (i) by altering the surface charge of the Fab paratope via mutagenesis (Figs. 2–4) and (ii) by modifying the density of monovalent anionic phospholipid in the membrane, particularly that of PS (Figs. 6–8).

As expected from the unspecific nature of electrostatic interactions, the mutation of basic residues as in R73E or K100E clearly diminished the partitioning of the antibody into membranes. However, albeit less potent, these mutants were still active in neutralization assays, an effect that correlated with a reduced ability to bind to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor weaker binding to immobilized PsVs or VL vesicles decorated with peptide. Thus, although comprising a modulatory factor, the mutation of basic residues as in R73E or K100E clearly diminished the partitioning of the antibody into membranes was lacking. A detailed examination of this process is important for two reasons: (i) to establish the lipid specificity range, which helps to evaluate the assumption that lipid auto-reactivity can prevent the production of 4E10-like antibodies through vaccination, and (ii) to establish the contribution of membrane-assisted MPER engagement to the biological function of 4E10.

Implications for the Mechanism of Neutralization by 4E10

Collectively, our data support the idea that direct interaction of 4E10 with the membrane is of high relevance for its neutralizing activity. Fig. 9 illustrates three non-exclusive mechanisms that have been previously proposed for the role of membrane interactions in the mechanism of 4E10 neutralization. We discuss below the possible ways by which the peripheral membrane interactions described in this work may support these mechanisms.

Accumulation in the Viral Membrane (Fig. 9, Left Structure)—Several authors have proposed a two-step mechanism for neutralization, in which 4E10 first attaches to the viral membrane (36, 37). This reversible step would be required to ensure subsequent binding to target MPER epitope, which is transiently exposed after fusion activation. Preattachment implies first sufficient free energy for driving spontaneous partitioning (Fig. 9, arrow a) and second competence of the Fab prebound to membranes for subsequent specific recognition of the epitope ligand (Fig. 9, arrow b). Our quantitative measurements (Figs. 5–7) are consistent with partitioning constants in the range of those measured for peripheral membrane proteins (28–30). Moreover, by combining fluorescence spectroscopy and photo-cross-linking assays, we were able to demonstrate the competence of antibody prebound to membrane for specific epitope binding (Fig. 8).

Vivid Effect (Fig. 9, Center Structure)—The surface of one virion particle only contains approximately 10 Env complexes, and consequently the non-immunogenic lipid component of the envelope constitutes the main structural-functional element of the HIV particle that is accessible from the external milieu (52). The reduced accessibility to the epitope precludes bifunctional binding and has been thus regarded to as an evasion mechanism (6). Lipid polyreactivity may increase the avidity of IgG by endowing 4E10 with the capacity to directly interact with membranes (6, 37). Our data support this notion,
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

although we note that the association of 4E10 with the membrane is driven by unspcific electrostatic interactions.

Structural Adaptation (Fig. 9, Right Structure)—The insertion of helical MPER epitope into the membrane interface imposes structural adaptations to the mechanism of recognition within the two-dimensional membrane milieu (17, 49). It has been reported that PS becomes accessible at the external leaflet of membranes in mature virions (for a discussion on this issue, see Ref. 22). Our data suggest that 4E10 takes the advantage of favorable electrostatic interactions with PS to enhance affinity for the membrane-bound epitope ligand (Figs. 3 and 7), most likely by providing an optimal orientation to the epitope-binding pocket relative to the membrane plane and sticking out MPER-helix.

In summary, our data support that electrostatic interactions with the negatively charged viral membrane surface contribute to enhance the affinity of 4E10 for the MPER helix and, hence, its potency. Assuming a constant lipid composition of virions across the different strains and isolates of HIV-1, we speculate that this adaptation could have evolved through maturation without compromising the neutralization breadth of the antibody.

Experimental Procedures

Materials—The peptides MPER_{664–690}, KKKK-DKWASL-WNWFDITNWLWYIKLIMIVG-KKKK; MPER_{671–693}, KKKK-DKWASL-WNWFDITNWLWYIKLIMIVGGLV-KK; and MPER_{671–693}/W672A-F673A, KKKK-NAADITNWLWYIKLIMIVGGLV-KK were synthesized in C-terminal carboxamide form by solid-phase methods using Fmoc (N-(9-fluorenylmethoxycarbonyl) chemistry, purified by reverse phase HPLC, and characterized by MALDI-TOF mass spectrometry (purity 95%). Peptides were routinely dissolved in DMSO (spectroscopy grade), and their concentrations were determined by the bicinchoninic acid microassay (Pierce). The experimental procedures described in Refs. 4 and 53 were followed for the production and purification of Fabs. Vector pEVOL, encoding a Tyr-trnasyn-cistron, suitable for the incorporation of photoreactive amino acid (BioSystems, Barcelona, Spain) and found to be within the experimental error. Vesicle flotation experiments in sucrose gradients were subsequently performed following the method described by Yethon et al. (55). In brief, 100 µl of a sample containing rhodamine-labeled liposomes and Fab (1.5 mM lipid and 1.5 µM Fab) was adjusted to a sucorese concentration of 1.4 M in a final volume of 300 µl and subsequently overlaid with 400- and 300-µl layers of 0.8 and 0.5 M sucorese, respectively. The gradient was centrifuged at 436,000 × g for 3 h in a TLA 120.2 rotor (Beckman Coulter, Brea, CA). After centrifugation, four 250-µl fractions were collected as depicted in Fig. 1A. The material adhered to the tubes was collected into a fifth fraction by washing with 250 µl of hot (100 ˚C) 1% (w/v) SDS. The different fractions were run on SDS-PAGE, and the presence of Fab was probed by Western blotting using a sandwich comprising a goat (anti-human Fab) antibody (Sigma) and a mouse (anti-goat) antibody-HRP conjugate (Santa Cruz). The results displayed in the figures are representative of at least two replicates.

Isothermal Titration Calorimetry—Titration experiments were performed with a VP-ITC microcalorimeter (MicroCal, Northampton, MA) at 25 °C. Prior to the experiment, the proteins were dialyzed overnight at 4 °C against 10 mM sodium phosphate (pH 7.5), 150 mM NaCl, and 10% glycerol. Samples containing protein and peptide solubilized in dialysis buffer were supplemented with 5 mM DPC and degassed immediately before each measurement. Fab 4E10 and mutant variants (3 µM) were titrated with peptide (40 µM). The volume of each injection was 10 µl. Peptide dilution heat was subtracted for data analysis. The binding isotherms were fitted to a one-site binding model using the program ORIGIN 7.0. The fitting procedure yields the stoichiometry (n), the binding constant (K_d), and the enthalpy (∆H) of the binding reaction. Each experiment was carried out once, where errors were obtained from the fitting procedure.

Cell Entry Inhibition—The cell entry inhibition assays were carried out as previously described (25, 53, 56). To run the experiments, HIV-1 pseudoviruses were first produced by transfection of human kidney HEK293T cells with the full-length env clones HXB2 or JRCSF (kindly provided by Jamie K. Scott and Naveed Gulzar, Simon Fraser University, Burnaby, Canada) using calcium phosphate. The cells were cotransfected with vectors pWXLP-GFP and pCMV8.91, encoding a green fluorescent protein and an env-deficient HIV-1 genome, respectively (generously provided by Patricia Villel, Consejo Superior de Investigaciones Científicas, Madrid, Spain). After 24 h, the medium was replaced with OptiMEM-GlutaMAX II (Invitrogen) without serum. Three days after transfection, the pseudovirus particles were harvested, passed through 0.45-µm pore sterile filters (Millex® HV; Millipore NV, Brussels, Belgium), and finally concentrated by ultracentrifugation in a sucrose gradient. Neutralization was determined using TZM-bl target cells (AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, contributed by J. Kappes). Samples were set up in duplicate in 96-well plates and incubated for 1.5 h at 37 °C with a 10–15% tissue culture infectious dose of pseudovirus. After antibody-pseudovirus coinucation, 11,000 target cells were added in the presence of 30 µg/ml DEAE-dextran (Sigma-Aldrich). Neutralization levels after 72 h were inferred from the reduction in the number of GFP-positive cells as determined by flow cytometry using a BD FACSCalibur flow cytometer (Becton Dickinson).
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

Fab Labeling with the NBD Fluorescent Probe and Spectroscopic Titration—Labeling with the polarity-sensitive NBD probe was performed as described (57, 58). In brief, a cysteine-substituted Fab derivative (W100bHC) was first generated by site-directed mutagenesis and modified with a sulfhydryl-specific iodoacetamide derivative of NBD. Fluorescence emission spectra were recorded with the excitation wavelength fixed at 470 nm. An emission spectrum of a sample lacking the fluorophore was subtracted from the spectrum of the equivalent sample containing the fluorophore. Partitioning curves were computed from the fractional changes in emitted NBD fluorescence when titrated with increasing lipid concentrations. The mole fraction partition coefficients, $K_x$, were determined by fitting the experimental values to a hyperbolic function (26),

$$\frac{F}{F_0} = 1 + \left( \frac{F_{\text{max}}/F_0 - 1}{K + [L]} \right)$$  \hspace{1cm} (Eq. 1)

where $[L]$ is the concentration of accessible lipid, and $K$ is the lipophilic concentration at which the bound peptide fraction is 0.5. Therefore, $K_x = [W]/K$, where $[W]$ is the molar concentration of water. The observed free energy of water membrane partitioning was subsequently calculated according to the following expression.

$$\Delta G_{\text{obs}} = -RT \ln K_x$$  \hspace{1cm} (Eq. 2)

For the estimation of the electrical potential at the membrane surface as a function of the PS content, the following equation was used,

$$\Psi_0 = \frac{2kT}{ze} \arcsinh \left[ \frac{\alpha}{\sigma} \right]^{1/2}$$  \hspace{1cm} (Eq. 3)

where $c$ is the number of ions per volume, and $\sigma$ is the surface charge density (33). To calculate the latter parameter, a surface area/phospholipid of 69.5 Å$^2$ was considered, and net charges of 0 and $-1$ were assigned to PC and PS, respectively (59).

Fab Labeling with Photo-activable Amino Acid—For the photo-cross-linking experiments, an amber codon specific for an engineered tRNA that translates the unnatural amino acid pBPA was encoded in the DNA sequence of the heavy chain of the 4E10 Fab. Procedures to express a 4E10 Fab mutant bearing BPA instead of Trp at position 100bHC were adapted from previous reports (34, 35). Synthesis of Fab and the engineered tRNA was induced with 0.4 mM isopropyl-D-thiogalactopyranoside and 4% (w/v) arabinose, respectively, in LB medium supplemented with 0.2 mg/liter pBPA. For the photo-cross-linking experiment, samples containing Fab bearing the Trp-100bHC × pBPA substitution at 1.5 µM and peptides at 10 µM were irradiated with UV light at 365 nm for 20 min at 4 °C using a UVP B-100AP lamp.

Author Contributions—E. R., J. M. M. C., K. T., and J. L. N. conceived and designed the experiments; E. R. produced Fabs and performed biophysical and biochemical characterizations with assistance of S. I. and M. G.-M.; E. R., J. M. M. C., and J. L. N. wrote the paper with input from K. T., and all of the authors reviewed it.

Acknowledgment—We thank Dr. Apellaniz for helpful discussions.

References

1. Zwick, M. B., Labrijn, A. F., Wang, M., Spennlehauer, C., Saphire, E. O., Binley, J. M., Moore, J. P., Stiegler, G., Katinger, H., Burton, D. R., and Parren, P. W. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892–10905

2. Binley, J. M., Wrin, T., Korber, B., Zwick, M. B., Wang, M., Chappy, C., Stiegler, G., Kunert, R., Zolla-Pazner, S., Katinger, H., Petropoulos, C. J., and Burton, D. R. (2006) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 80, 13232–13252

3. Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Baier, R. T., Chakrabarti, B., Sharma, S. K., Alam, S. M., Wang, T., Yang, Y., Zhang, B., Migueles, S. A., et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406–412

4. Jacob, R. A., Moyo, T., Schomaker, M., Abrahams, F., Grauj Pujol, B., and Dorfman, J. R. (2015) Anti-V3/glycan and anti-MPER neutralizing antibodies, but not anti-V2/glycan site antibodies, are strongly associated with greater anti-HIV-1 neutralization breadth and potency. J. Virol. 89, 5264–5275

5. Montero, M., van Houten, N. E., Wang, X., and Scott, J. K. (2008) The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72, 54–84

6. Klein, F., Mouquet, H., Densonovic, P., Scheif, J. D., Scharf, L., and Nussenzweig, M. C. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199–1204

7. Kim, A. S., Leaman, D. P., and Zwick, M. B. (2014) Antibody to gp41 MPER alters functional properties of HIV-1 Env without complete neutralization. PLoS Pathog. 10, e1004271

8. Sánchez-Martínez, S., Lorizate, M., Hermann, K., Kunert, R., Basañez, G., and Nieva, J. L. (2006) Specific phospholipid recognition by human immunodeficiency virus type 1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 580, 2395–2399

9. Matyas, G. R., Beck, Z., Karasavvas, N., and Alving, C. R. (2009) Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta 1788, 660–665

10. Finton, K. A., Larimore, K., Larmam, H. B., Friend, D., Correnti, C., Ruper, P. B., Elledge, S. J., Greenberg, P. D., and Strong, R. K. (2013) Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 9, e1003639

11. Chen, J., Frey, G., Peng, H., Rits-Voeloch, S., Garrity, J., Seaman, M. S., and Chen, B. (2014) Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 88, 1249–1258

12. Irimia, A., Sarkar, A., Stanfield, R. L., and Wilson, I. A. (2016) Crystallographic identification of lipid as an integral component of the epitope of HIV broadly neutralizing antibody 4E10. Immunity 44, 21–31

13. Alving, C. R. (2008) 4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues. AIDS 22, 649–651

14. Haynes, B. F., Fleming, J., St Clair, E. W., Katinger, H., Stiegler, G., Kunert, R., Robinson, J., Searce, R. M., Plonk, K., Staats, H. F., Ortel, T. L., Liao, H. X., and Alam, S. M. (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906–1908

15. Doyle-Cooper, C., Hudson, K. E., Cooper, A. B., Ota, T., Skog, P., Dawson, P. E., Zwick, M. B., Schief, W. R., Burton, D. R., and Nemazee, D. (2013) Immune tolerance to B cells in non-naïve mice expressing broadly neutralizing HIV antibody 4E10. J. Immunol. 189, 3186–3191

16. Verkoczy, L., Kelsoe, G., and Haynes, B. F. (2014) HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 10, e1004073

17. Sánchez-Martínez, S., Lorizate, M., Katinger, H., Kunert, R., and Nieva, J. L. (2006) Membrane association and epitope recognition by HIV-1 broadly neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res. Hum. Retroviruses 22, 998–1006
Peripheral Membrane Interactions of an Anti-HIV-1 Antibody

18. Rujas, E., Gulzar, N., Morante, K., Tsumoto, K., Scott, J. K., Nieva, J. L., and Caaveiro, J. M. (2015) Structural and thermodynamic basis of epitope binding by neutralizing and nonneutralizing forms of the anti-HIV-1 antibody 4E10. J. Virol. 89, 11975–11989.

19. Rujas, E., Gulzar, N., Morante, K., Tsumoto, K., Scott, J. K., Nieva, J. L., and Caaveiro, J. M. (2016) Reply to “The broadly neutralizing, anti-HIV antibody 4E10: an open and shut case?”. J. Virol. 90, 3276–3277.

20. Bird, G. H., Irimia, A., Ofek, G., Kwong, P. D., Wilson, I. A., and Hristova, K. (2008) Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies. Nat. Struct. Mol. Biol. 21, 1058–1067.

21. Lemmon, M. A. (2008) Membrane recognition by phospholipid-binding domains. Nat. Rev. Cell Biol. 9, 99–111.

22. Huarte, N., Carravilla, P., Cruz, A., Lorizate, M., Nieto-Garai, I. A., Krauslich, H. G., Pérez-Gil, J., Requejo-Isidro, J., and Nieva, J. L. (2016) Functional organization of the HIV lipid envelope. Sci. Rep. 6, 34190.

23. Kwon, Y. D., Georgiev, I. S., Ofek, G., Zhang, B., Asokan, M., Baier, R. T., Bao, A., Caruso, W., Chen, X., Choe, M., Druz, A., Ko, S. Y., Louder, M. K., McKee, K., O’Dell, S., et al. (2016) Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design. J. Virol. 90, 5899–5914.

24. Rujas, E., Caaveiro, J. M., Partida-Hanon, A., Gulzar, N., Morante, K., Apellániz, B., García-Porras, M., Bruix, M., Tsumoto, K., Scott, J. K., Jiménez, M. A., and Nieva, J. L. (2016) Structural basis for broad neutralization of HIV-1 through the molecular recognition of 10E8 helical epitope at the membrane interface. Sci. Rep. 6, 38177.

25. Apellániz, B., Rujas, E., Serrano, S., Morante, K., Tsumoto, K., Caaveiro, J. M., Jiménez, M. A., and Nieva, J. L. (2015) The atomic structure of the HIV-1 gp41 transmembrane domain and its connection to the immunogenic membrane-proximal external region. J. Biol. Chem. 290, 12999–13015.

26. White, S. H., Wimley, W. C., and Alam, S. M. (2009) Protein folding in membranes: determining energetics of peptide-bilayer interactions. Methods Enzymol. 295, 62–87.

27. Lacowicz, J. R. (2006) Principles of Fluorescence Spectroscopy, 3rd Ed., pp. 205–235, Springer-Verlag, New York Inc., New York.

28. Nomikos, M., Mulgrew-Nesbit, A., Pallavi, P., Mihalyne, G., Zaitseva, I., Sun, Z. Y., Oh, K. J., Kim, M., Yu, J., Brusic, V., Song, L., Qiao, Z., Wang, J. H., Wagner, G., and Reinh erz, E. L. (2008) HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Proc. Natl. Acad. Sci. U.S.A. 105, 1529–1534.

29. Dennison, S. M., Stewart, S. M., Stempel, K. C., Hanstock, P. M., and Nieva, J. L. (2014) The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring. AIDS 19, 1725–1737.

30. Salzedo, K., West, J. T., and Hunter, E. (1999) A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73, 2469–2480.

31. Sáez-Cirión, A., Nir, S., Lorizate, M., Agirre, A., Cruz, A., Pérez-Gil, J., and Nieva, J. L. (2002) Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J. Biol. Chem. 277, 21776–21785.

32. White, S. H., and Wimley, W. C. (1998) Membrane protein folding and interactions. J. Biol. Chem. 273, 3817–3821.

33. Young, T. S., Ahmad, L., Yin, J. A., and Schultz, P. G. (2010) An enhanced system for unnatural amino acid mutagenesis in E. coli. J. Mol. Biol. 395, 361–374.

34. Abe, R., Caaveiro, J. M., Kozuka-Hata, H., Oyama, M., and Tsumoto, K. (2012) Mapping ultra-weak protein-protein interactions between heme transporters of Staphylococcus aureus. J. Biol. Chem. 287, 16477–16487.

35. Alam, S. M., Morelli, M., Dennison, S. M., Liao, H. X., Zhang, R., Xia, S. M., Rits-Volloch, S., Sun, L., Harrison, S. C., Haynes, B. F., and Chen, B. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 106, 20234–20239.

36. Haynes, B. F., Nicely, N. L., and Alam, S. M. (2010) HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? Nat. Struct. Mol. Biol. 17, 543–545.

37. Wyatt, R., and Sodroski, J. (1998) The HIV-1 envelope glycoproteins: self-association, oligomerization, and virus infectivity. Science 280, 1884–1888.

38. McLaughlin, S. (1989) The electrostatic properties of membranes. Annu. Rev. Biophys. 18, 113–136.

39. Young, T. S., Ahmad, L., Yin, J. A., and Schultz, P. G. (2010) An enhanced system for unnatural amino acid mutagenesis in E. coli. J. Mol. Biol. 395, 361–374.

40. Abe, R., Caaveiro, J. M., Kozuka-Hata, H., Oyama, M., and Tsumoto, K. (2012) Mapping ultra-weak protein-protein interactions between heme transporters of Staphylococcus aureus. J. Biol. Chem. 287, 16477–16487.

41. Alam, S. M., Morelli, M., Dennison, S. M., Liao, H. X., Zhang, R., Xia, S. M., Rits-Volloch, S., Sun, L., Harrison, S. C., Haynes, B. F., and Chen, B. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 106, 20234–20239.

42. Haynes, B. F., Nicely, N. L., and Alam, S. M. (2010) HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? Nat. Struct. Mol. Biol. 17, 543–545.

43. Wyatt, R., and Sodroski, J. (1998) The HIV-1 envelope glycoproteins: self-association, oligomerization, and virus infectivity. Science 280, 1884–1888.

44. McLaughlin, S. (1989) The electrostatic properties of membranes. Annu. Rev. Biophys. 18, 113–136.

45. Young, T. S., Ahmad, L., Yin, J. A., and Schultz, P. G. (2010) An enhanced system for unnatural amino acid mutagenesis in E. coli. J. Mol. Biol. 395, 361–374.

46. Abe, R., Caaveiro, J. M., Kozuka-Hata, H., Oyama, M., and Tsumoto, K. (2012) Mapping ultra-weak protein-protein interactions between heme transporters of Staphylococcus aureus. J. Biol. Chem. 287, 16477–16487.

47. Alam, S. M., Morelli, M., Dennison, S. M., Liao, H. X., Zhang, R., Xia, S. M., Rits-Volloch, S., Sun, L., Harrison, S. C., Haynes, B. F., and Chen, B. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 106, 20234–20239.

48. Haynes, B. F., Nicely, N. L., and Alam, S. M. (2010) HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? Nat. Struct. Mol. Biol. 17, 543–545.

49. Wyatt, R., and Sodroski, J. (1998) The HIV-1 envelope glycoproteins: self-association, oligomerization, and virus infectivity. Science 280, 1884–1888.
of size distribution, trapped volume and ability to maintain a membrane potential. *Biochim. Biophys. Acta* **812**, 55–65

55. Yethon, J. A., Epand, R. F., Leber, B., Epand, R. M., and Andrews, D. W. (2003) Interaction with a membrane surface triggers a reversible conformational change in Bax normally associated with induction of apoptosis. *J. Biol. Chem.* **278**, 48935–48941

56. Serrano, S., Araujo, A., Apellániz, B., Bryson, S., Carravilla, P., de la Arada, I., Huarte, N., Rujas, E., Pai, E. F., Arrondo, J. L., Domene, C., Jiménez, M. A., and Nieva, J. L. (2014) Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design. *J. Biol. Chem.* **289**, 6565–6580

57. Shepard, L. A., Heuck, A. P., Hamman, B. D., Rossjohn, J., Parker, M. W., Ryan, K. R., Johnson, A. E., and Tweten, R. K. (1998) Identification of a membrane-spanning domain of the thiol-activated pore-forming toxin Clostridium perfringens perfringolysin O: an α-helical to β-sheet transition identified by fluorescence spectroscopy. *Biochemistry* **37**, 14563–14574

58. Heuck, A. P., Hotze, E. M., Tweten, R. K., and Johnson, A. E. (2000) Mechanism of membrane insertion of a multimeric beta-barrel protein: perfringolysin O creates a pore using ordered and coupled conformational changes. *Mol. Cell* **6**, 1233–1242

59. Rand, R. P., and Parsegian, V. A. (1989) Hydration forces between phospholipid bilayers. *Biochim. Biophys. Acta* **988**, 351–376